Last updated on November 2019

A Study to Assess the Safety Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration


Brief description of study

Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vasoendothelial growth factor (anti-VEGF) therapy) which must be administered by an injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of patients with exudative AMD, and could offer an alternative, safer and less burdensome therapy.

Clinical Study Identifier: NCT03869684

Find a site near you

Start Over

Senju Investigational Site

Redlands, CA United States
  Connect »

Senju Investigational Site

Melbourne, FL United States
  Connect »

Senju Investigational Site

Tallahassee, FL United States
  Connect »

Senju Investigational Site

Indianapolis, IN United States
  Connect »

Senju Investigational Site

Arlington, TX United States
  Connect »

Senju Investigational Site

San Antonio, TX United States
  Connect »

Senju Investigational Site

Houston, TX United States
  Connect »

Senju Investigational Site

Baltimore, MD United States
  Connect »

Senju Investigational Site

The Woodlands, TX United States
  Connect »

Senju Investigational Site

Salt Lake City, UT United States
  Connect »

Senju Investigational Site

Phoenix, AZ United States
  Connect »

Senju Investigational Site

Clearwater, FL United States
  Connect »

Senju Investigational Site

Altamonte Springs, FL United States
  Connect »